Last reviewed · How we verify
NCT07232290
Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Phase 2 trial testing Flonoltinib 75mg in Polycythemia Vera (PV) in 60 participants. Currently enrolling.
30 July 2027
Quick facts
| Lead sponsor | Chengdu Zenitar Biomedical Technology Co., Ltd |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 23 September 2025 |
| Primary completion | 30 July 2027 |
| Estimated completion | 28 February 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Flonoltinib 75mg — full drug profile →
- Flonoltinib 100mg — full drug profile →
- Flonoltinib 125mg — full drug profile →
- Extended Phase Dose Group — full drug profile →
Conditions studied
- Polycythemia Vera (PV) — all drugs for Polycythemia Vera (PV) →
Sponsor
Chengdu Zenitar Biomedical Technology Co., Ltd — full company profile →
Who can join
18 and older, any sex, with Polycythemia Vera (PV). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial adopts an open, randomized, parallel controlled, multicenter clinical trial design planning to enroll patients with polycythemia vera who are resistant/intolerant to hydroxyurea or interferon。The study divided into two stages: dose exploration stage: three dose groups are tentatively set, with three subjects in each group, totaling nine subjects in each group; Dose extension stage: Based on the safety, efficacy, and pharmacokinetic results of the comprehensive dose exploration stage, 2-3 dose groups are planned to be selected for dose extension trials.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07232290
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Flonoltinib 75mg
Trials testing the same drug.
- NCT07317700 — A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis · Phase 3 · recruiting
Other recruiting trials for Polycythemia Vera (PV)
Currently open trials in the same condition.
- NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
- NCT04655092 — Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients · Phase 3 · recruiting
Other Chengdu Zenitar Biomedical Technology Co., Ltd trials
Trials by the same sponsor.
- NCT07339748 — A Clinical Study of ZL-85FA Tablets · Phase 1, PHASE2 · not yet recruiting
- NCT07443306 — A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patient · Phase 2 · recruiting
- NCT07317700 — A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis · Phase 3 · recruiting
- NCT07193589 — A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis · Phase 2 · recruiting
- NCT07011056 — A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07232290 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chengdu Zenitar Biomedical Technology Co., Ltd
- Last refreshed: 4 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07232290.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing